广东省自然科学基金(S2011010005830)
- 作品数:1 被引量:6H指数:1
- 相关作者:麦丽萍康彦红劳海燕余细勇陈纪言更多>>
- 相关机构:南方医科大学广东省人民医院更多>>
- 发文基金:国家自然科学基金广东省自然科学基金广东省医学科学技术研究基金更多>>
- 相关领域:医药卫生更多>>
- SITE-SPECIFIC HYPOMETHYLATION WITHIN PROMOTER CPG ISLAND OF PON1 WAS ASSOCIATED WITH BLEEDING EVENTS IN DUAL ANTIPLATELET-TREATED HAN CHINESE PATIENTS AFTER PCI
- To evaluate the role of the DNA methylation of the CpG island within the PON1 promoter on the clinical efficac...
- 钟诗龙康彦红陈纪言李新新张莹劳海燕余细勇
- Plasma miR-126 as a potential marker predicting major adverse cardiac events in dual antiplatelet-treated patients after percutaneous coronary intervention
- Aims:Antiplatelet treatment could cause a change in plasma levels of platelet microRNAs(miRNAs).However,it is ...
- 余细勇Ji-Yan ChenZhi-Wei ZhengHong WuLi-Wen LiZhi-Wei ZhangZhi-Hong ChenQiu-Xiong LinYa-Ling Han钟诗龙
- 文献传递
- PON1基因启动子多态性及非遗传因素对PCI术后抗血小板治疗临床效应的影响被引量:6
- 2012年
- 目的对氧磷脂酶1(PON1)启动子CpG岛区基因多态性可能会影响氯吡格雷的抗血小板疗效。本研究探讨PON1基因启动子区多态性位点-108C/T,-126 G/C和-162G/A以及高血压、糖尿病等非遗传因素对行经皮冠状动脉介入治疗(PCI术)的冠心病患者氯吡格雷抗血小板临床效应的影响。方法根据纳入和排除标准,入选在广东省人民医院行PCI术患者538名,收集患者的临床资料,采用PCR直接测序的方法检测基因型,使用SAS9.1和HPlus软件分析其与氯吡格雷抗血小板效应的关系。结果 PON1启动子区-108C/T,-126 G/C和-162G/A位点,基因型为野生型或突变性对氯吡格雷抗血小板效应差异均无显著性(P>0.05);患者合并高血压[HR(95%CI)=3.837]、糖尿病(HR=2.715)或使用钙离子拮抗剂(HR=2.686)时,PCI术后出现MACE的风险较高(P<0.05)。结论 PON1基因启动子CpG岛区-108C/T,-126 G/C和-162G/A基因变异对接受氯吡格雷抗血小板治疗的冠心病患者在PCI术后出现主要不良心脏事件(MACE)无明显影响。患者合并高血压、糖尿病或使用钙离子拮抗剂会增加PCI术后出现MACE的风险。
- 康彦红劳海燕陈秀云麦丽萍余细勇陈纪言钟诗龙
- 关键词:对氧磷脂酶1抗血小板治疗主要不良心脏事件非遗传因素
- Site-specific hypomethylation within promoter CpG island of PON1 was associated with bleeding events in dual antiplatelet-troatod Han Chinese patients after PCI
- <正>Aim:To evaluate the role of the DNA methylation of the CpG island within the PON1 promoter on the clinical ...
- Shi-long ZHONGYan-hong KANGJi-yan CHENXin-xin LIYing ZHANGHai-yan LAOXi-yong YU
- 关键词:CLOPIDOGREL
- 文献传递
- Plasma miR-126 as a potential marker predicting major adverse cardiac events in patients after percutaneous coronary intervention
- AIM:Circulating miRNAs have been considered as promising novel biomarkers for prognosis of cardiovascular dise...
- ZHENG Zhi-weiYU Xi-yongCHEN Ji-yanWU HongLI Li-wenCHEN Zhi-hongHAN Ya-LingZHONG Shi-Long
- Plasma miR-197 and miR-486-3p as potential novel diagnostic biomarkers for hypertension
- AIM:Circulating microRNAs(miRNAs) have attracted much attention as promising novel markers for various disease...
- LI Xin-xinLIU Xiao-qingFENG Ying-qingYU Xi-yongMAI Li-pingZHENG Wei-zhiZHONG Shi-long
- PON1基因启动子多态性及非遗传因素对PCI术后抗血小板治疗临床效应的影响
- 目的:对氧磷脂酶1(PON1)启动子CpG岛区基因多态性可能会影响氯吡格雷的抗血小板疗效。本研究探讨PON1基因启动子区多态性位点-108C/T、-126 G/C和-162G/A以及高血压、糖尿病等非遗传因素对行经皮冠状...
- 康彦红劳海燕陈秀云麦丽萍余细勇陈纪言钟诗龙
- SITE-SPECIFIC HYPOMETHYLATION WITHIN PROMOTER CPG ISLAND OF PON1 WAS ASSOCIATED WITH BLEEDING EVENTS IN DUAL ANTIPLATELET-TREATED HAN CHINESE PATIENTS AFTER PCI
- <正>To evaluate the role of the DNA methylation of the CpG island within the PON1 promoter on the clinical effi...
- 钟诗龙康彦红陈纪言李新新张莹劳海燕余细勇
- CYP2C19 and PON1 genetic variants as potential predictors for the risk of bleeding in antiplatelet-treated patients
- AIM:Bleeding has emerged as an important outcome in antiplatelet treatment after percutaneous coronary interve...
- ZHONG Shi-longYU Xi-yongWU HongZHANG BinKANG Yan-hongZHENG Zhi-weiWANG LingLIN Qiu-xiongSHAN Zhi-xinCHEN Ji-yan